<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048498</url>
  </required_header>
  <id_info>
    <org_study_id>NEX-18-01</org_study_id>
    <nct_id>NCT05048498</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Tolerability and Safety of NEX-18a</brief_title>
  <official_title>An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanexa AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanexa AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, tolerability and pharmacokinetics of NEX-18a, a&#xD;
      long-acting injectable azacitidine, in patients diagnosed with intermediate 2 or higher-risk&#xD;
      MDS, CMML, or AML and already on treatment with azacitidine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since 2010, subcutaneous treatment with azacitidine has been the first-line treatment for&#xD;
      patients with high-risk MDS. Azacitidine has been established as a standard of care and is&#xD;
      described in the National Comprehensive Cancer Network (NCCN) guidelines as a core component&#xD;
      of optimal treatment of MDS. However, mainly due to its short half-life (41 minutes) when&#xD;
      administered subcutaneously azacitidine should, according to the approved label, be&#xD;
      administered for seven consecutive days at a dose of 75 mg/m2 body surface area (BSA) each&#xD;
      28-day cycle. In the Nordic Guidelines, two alternative dosing schedules may also be&#xD;
      considered: 100 mg/m2 BSA sc day 1-5 or 75 mg/m2 BSA sc day 1-5 + 8-9 (to avoid injection&#xD;
      during weekends).&#xD;
&#xD;
      Nanexa AB has developed NEX-18a, a subcutaneous injection of azacitidine with&#xD;
      extended-release based on the drug delivery system, PharmaShellÂ®. Drug particles are enclosed&#xD;
      in a coating with controlled solubility, and as the coating dissolves over time the drug is&#xD;
      released in a predefined manner. This technique provides a way to create drugs with a&#xD;
      prolonged release for parenteral administration. The technology used by Nanexa to manufacture&#xD;
      the coating is via Atomic Layer Deposition (ALD). In ALD, reactive gases are used which build&#xD;
      up a surface coating with high precision, atomic layer by atomic layer.&#xD;
&#xD;
      NEX-18a will offer a benefit to current azacitidine treatment with a reduction of&#xD;
      subcutaneous administrations, decreased need for pre-medication, and will reduce the time&#xD;
      each patient has to spend in the hospital in order to receive the treatment in each cycle. In&#xD;
      addition, the patients will spend less time traveling to and from the hospital and from a&#xD;
      health care perspective, one injection instead of seven per cycle will reduce the time and&#xD;
      the resources the health care provider dedicates to treating the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematology and Clinical Chemistry analyses</measure>
    <time_frame>0-30 days</time_frame>
    <description>Change from baseline to 30 days follow-up. Descriptive individual data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0-30 days</time_frame>
    <description>Change from baseline to 30 days follow-up. Descriptive individual data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>0-30 days</time_frame>
    <description>Change from baseline to 30 days follow-up. Descriptive individual data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>0-30 days</time_frame>
    <description>Change from baseline to 30 days follow-up. Descriptive individual data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerance (injection site)</measure>
    <time_frame>0-30 days</time_frame>
    <description>Change from baseline to 30 days follow-up. Descriptive individual data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant medications/therapy</measure>
    <time_frame>0-30 days</time_frame>
    <description>Change from baseline to 30 days follow-up. Descriptive individual data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC-time curve</measure>
    <time_frame>0-24 h</time_frame>
    <description>From time 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0-last</measure>
    <time_frame>0-336 h</time_frame>
    <description>From time 0 to last</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 to infinity</measure>
    <time_frame>0-336 h</time_frame>
    <description>From time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration</measure>
    <time_frame>0-336 h</time_frame>
    <description>Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration over time</measure>
    <time_frame>0-336 h</time_frame>
    <description>Plasma Concentration at 336h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life measurement</measure>
    <time_frame>0-336 h</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of distribution</measure>
    <time_frame>0-336 h</time_frame>
    <description>Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination</measure>
    <time_frame>0-336 h</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerance of NEX-18a</measure>
    <time_frame>0-30 days</time_frame>
    <description>Change from baseline to 30 days follow-up. Descriptive individual data. The local tolerance will be measured by inspection of injection sites. Pain, tenderness erythema/redness, and induration/swelling will be assessed by a four-grade scale where 1 is mild and 4 is potentially life threatening.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Myelodysplastic Syndromes (MDS)</condition>
  <condition>Chronic Myelomonocytic Leukemia (CMML)</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Azacitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment phase 1: the patients will receive regular treatment with azacitidine for 4 days.&#xD;
Treatment phase 2: the patients will receive regular treatment with azacitidine for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEX-18a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment phase 1: the azacitidine dose for day 5 will be replaced by a single dose NEX-18a&#xD;
Treatment phase 2: the azacitidine dose for day 4 and 5 will be replaced by a single dose NEX-18a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEX-18a injection</intervention_name>
    <description>In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.&#xD;
In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection.</description>
    <arm_group_label>NEX-18a</arm_group_label>
    <other_name>PharmaShell</other_name>
    <other_name>Azacitidine</other_name>
    <other_name>5-azacitidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine Injection</intervention_name>
    <description>In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.</description>
    <arm_group_label>Azacitidine</arm_group_label>
    <other_name>Azacitidine</other_name>
    <other_name>5-azacitidine</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written informed consent prior to any study specific procedures.&#xD;
&#xD;
          2. Female and male patients â¥ 18 years of age.&#xD;
&#xD;
          3. Body Mass Index (BMI) &gt; 19 and &lt; 30 kg/m2 BSA at screening.&#xD;
&#xD;
          4. Treatment with azacitidine corresponding to 100 mg/m2 BSA x 5 per treatment cycle for&#xD;
             at least six cycles for:&#xD;
&#xD;
               1. intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the&#xD;
                  International Prognostic Scoring System (IPSS)&#xD;
&#xD;
               2. chronic myelomonocytic leukemia (CMML) with 10-29 % marrow blasts&#xD;
&#xD;
               3. acute myeloid leukemia (AML) according to World Health Organization (WHO)&#xD;
                  classification&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.&#xD;
&#xD;
          6. Recovery of Hematology and Clin. Chemistry assessment according to clinical praxis at&#xD;
             the start of the last azacitidine treatment cycle before the screening visit.&#xD;
&#xD;
          7. Female subject must be of non-childbearing potential (defined as pre-menopausal&#xD;
             females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or&#xD;
             as post-menopausal females defined as 12 months' amenorrhoea [in questionable cases a&#xD;
             blood sample with simultaneous follicle stimulation hormone 25-140 IE/L and estradiol&#xD;
             &lt; 200 pmol/L is confirmatory])&#xD;
&#xD;
          8. Male patients must agree to use an adequate method of contraception. Male patients who&#xD;
             are sexually active must use, with their partner, a condom AND one of the following&#xD;
             methods of highly effective contraception from the time of IMP administration until 90&#xD;
             days after the last dose of IMP.&#xD;
&#xD;
               1. oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable or&#xD;
                  implanted hormonal contraceptives&#xD;
&#xD;
               2. intrauterine device&#xD;
&#xD;
               3. intrauterine system (for example progestin-releasing coil)&#xD;
&#xD;
               4. vasectomized male (with appropriate post vasectomy documentation of the absence&#xD;
                  of sperm in the ejaculate)&#xD;
&#xD;
               5. bilateral tubal occlusion or hysterectomy&#xD;
&#xD;
          9. Willingness and ability to comply with study procedures, visit schedules, study&#xD;
             restrictions, and requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient has participated in any other investigational/interventional trial&#xD;
             including an investigational drug within 30 days (or five half-lives of the study drug&#xD;
             prior to screening, whichever is longer) prior to screening.&#xD;
&#xD;
          2. Diagnosis of malignant disease within the previous 5 years (excluding basal cell&#xD;
             carcinoma of the skin without complications, &quot;in-situ&quot; carcinoma of the cervix or&#xD;
             breast, or other local malignancy excised or irradiated with a high probability of&#xD;
             cure).&#xD;
&#xD;
          3. Any significant medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the patient from participating in the study.&#xD;
&#xD;
          4. The patient has a history of alcohol abuse or drug abuse within the past 12 months.&#xD;
&#xD;
          5. Any condition including the presence of laboratory abnormalities, which places the&#xD;
             patient at unacceptable risk if he/she were to participate in the study.&#xD;
&#xD;
          6. Lack of suitability for participation in the study, for any reason, judged by the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla Olsson StrÃ¶mberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Owe Luhr, MD, PhD</last_name>
    <phone>+46 70 605 10 05</phone>
    <email>owe.luhr@nanexa.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Nehlin, RN</last_name>
    <phone>+ 46 734 20 23 20</phone>
    <email>maria.nehlin@nanexa.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Tobiasson, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Magnus Tobiasson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva HellstrÃ¶m Lindberg, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin JÃ¤dersten, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniska Forsknings och Utvecklings Enheten KFUE</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Olsson-StrÃ¶mberg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ulla Olsson-StrÃ¶mberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Ejerblad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin HÃ¶glund, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

